GOLPH2在恶性肿瘤中作用及机制的研究进展

doi:10.11904/j.issn.1002-3070.2017.05.014

摘要/Abstract

摘要： 目前检测血清肿瘤标记物仍被认为是早期诊断肿瘤及监测肿瘤的有效手段之一。高尔基体磷酸化蛋白2(Golgi phosphoprotein 2,GOLPH2)是存在于高尔基体的一种II型跨膜蛋白,近年来很多研究认为GOLPH2是最有潜力的早期诊断肿瘤的血清标志物之一。此外,亦有多项研究显示GOLPH2与肺癌、胃癌、前列腺癌等癌症的预后相关,GOLPH2参与机体免疫调节、细胞内信号因子的激活和降解以及促进上皮间质转化(Epithelial-mesenchymal transition,EMT),并且通过这些机制促进肿瘤的进展和转移,从而降低患者的无病生存率(Disease-free survival,DFS)和总生存率(Overall survival,OS)。本文就目前GOLPH2在各种恶性肿瘤中的作用及机制研究进展作一综述。

关键词: GOLPH2, 肿瘤, 血清标记物, 转移

Abstract: The current detection of serum tumor markers is still considered to be one of convenient and effective means for early diagnosis of tumor and monitoring tumor progression.Golgi phosphoprotein 2(GOLPH2)is a type II transmembrane protein presenting in the Golgi apparatus.In recent years,many studies have suggested that GOLPH2 is one of the most promising early serum markers for early diagnosis of tumor.In addition,many studies have beer shown that GOLPH2 is related to prognosis of lung cancer,gastric cancer,prostate cancer and other cancer-related prognosis involved in immune regulation,intracellular signal factor activation and degradation and promote epithelial-mesenchymal transition(EMT).Through these mechanisms to promote tumor progression and metastasis,GOLPH2 reduces the disease-free survival(DFS)and overall survival(OS).In this paper,we review the role of GOLPH2 in the progress and a variety of malignant tumors.

Key words: GOLPH2, Tumor, Serum markers, Metastasis

中图分类号:

方杏华综述, 宋英审校. GOLPH2在恶性肿瘤中作用及机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 458-462.

FANG Xinghua, SONG Ying. Research advances in the role of GOLPH2 in malignant tumor and its mechanism[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 458-462.

参考文献

1 吴菲,林国桢,张晋昕.我国恶性肿瘤发病现状及趋势[J].中国肿瘤,2012,21(2):81-85.
2 Ba MC,Long H,Tang YQ,et al.GP73 expression and its significance in the diagnosis of hepatocellular carcinoma:a review[J].Int J Clin Exp Pathol,2012,5(9):874-881.
3 Iftikhar R,Kladney RD,Havlioglu N,et al.Disease-and cell-specific expression of GP73 in human liver disease[J].Am J Gastroenterol,2004,99:1087-1095.
4 Wright LM,Yong S,Picken MM,et al.Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73(GOLPH2)[J].Int J Clin Exp Pathol,2009,2(1):34-47.
5 Bachert C,Fimmel C,Linstedt AD.Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma[J].Traffic,2007,8(10):1415-1423.
6 Byrne AM,Bekiaris S,Duggan G,et al.Golgi phosphoprotein 2(GOLPH2)is a novel bile acid-responsive modulator of oesophageal cell migration and invasion[J].Br J Cancer,2015,113(9):1332-1342.
7 Block TM,Comunale MA,Lowman M,et al.Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in wood chucks and humans[J].Proc Natl Acad Sci U S A,2005,102(3):779-784.
8 Marrero JA,Romano PR,Nikolaeva O,et al.GP73,a resident Golgi glycoprotein,is a novel serum marker for hepatocellular carcinoma[J].J Hepatol,2005,43(6):1007-1012.
9 Coppola JM,Bhojani MS,Ross BD,et al.A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness[J].Neoplasia,2008,10(4):363-370.
10 Hu JS,Wu DW,Liang S,et al.GP73,a resident Golgi glycoprotein,is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population[J].Med Oncol,2010,27(2):339-345.
11 Mao Y,Yang H,Xu H,et al.Golgi protein 73(GOLPH2)is a valuable serum marker for hepatocellular carcinoma[J].Gut,2010,59(12):1687-1693.
12 Zhang F,Gu Y,Xiang L,et al.Up-regulated Golgi phosphoprotein 2(GOLPH2)expression in lung adenocarcinoma tissue[J].Clin Biochem,2010,43(12):983-991.
13 Varambally S,Laxman B,Mehra R,et al.Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer[J].Neoplasia,2008,10(11):1285-1294.
14 Riener MO,Stenner F,Liewen H,et al.Golgi phosphoprotein 2(GOLPH2)expression in liver tumors and its value as a serum marker in hepatocellular carcinomas[J].Hepatology,2009,49(5):1602-1609.
15 Chen MH,Jan YH,Chang PM,et al.Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma[J].Ann Surg Oncol,2013,20(3):616-624.
16 Jiang K,Li W,Shang S,et al.Aberrant expression of Golgi protein 703 is indicative of a poor outcome in hepatocellular carcinoma[J].Oncol Rep,2016,35(4):2141-2150.
17 Ye QH,Zhu WW,Zhang JB,et al.GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis[J].Cancer Cell,2016,30(3):444-458.
18 Kristiansen G,Fritzsche FR,Wassermann K,et al.GOLPH2 protein expression as a novel tissue biomarker for prostate cancer:implications for tissue-based diagnostics[J].Br J Cancer,2008,99(6):939-948.
19 Liu G,Zhang Y,He F,et al.Expression of GOLPH2 is associated with the progression of and poor prognosis in gastric cancer[J].Oncol Rep,2014,32(5):2077-2085.
20 Donizy P,Kaczorowski M,Biecek P,et al.Golgi-related proteins GOLPH2(GP73/GOLM1)and GOLPH3(GOPP1/MIDAS)in cutaneous melanoma:patterns of expression and prognostic significance[J].Int J Mol Sci,2016,17(10):1619.
21 Byrne AM,Bekiaris S,Duggan G,et al.Golgi phosphoprotein 2(GOLPH2)is a novel bile acid-responsive modulator of oesophageal cell migration and invasion[J].Br J Cancer,2015,113(9):1332-1342.
22 Fritzsche FR,Kristiansen G,Riener MO,et al.GOLPH2 expression may serve as diagnostic marker in seminomas[J].BMC Urol,2010,10(1):4.
23 Kim HJ,Cantor H.CD4 T-cell subsets and tumor immunity:the helpful and the not-so-helpful[J].Cancer Immunol Res,2014,2(2):91-98.
24 Tang QF,Ji Q,Tang Y,et al.Golgi phosphoprotein 2 down-regulates the Th1 response in human gastric cancer cells by suppressing IL-12A[J].Asian Pac J Cancer Prev,2013,14(10):5747-5751.
25 Kumari N,Dwarakanath BS,Das A,et al.Role of interleukin-6 in cancer progression and therapeutic resistance[J].Tumor Biol,2016,37(9):11553-11572.
26 Liang H,Block TM,Wang M,et al.Interleukin-6 and Oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73[J].Cancer Biomark,2011,11(4):161-171.
27 Regad T.Targeting RTK signaling pathways in cancer[J].Cancers,2015,7(3):1758-1784.
28 Chen X,Wang Y,Tao J,et al.mTORC1 up-regulates GP73 to promote proliferation and migration of hepatocellular carcinoma cells and growth of xenograft tumors in mice[J].Gastroenterology,2015,149(3):741-752.
29 Shah M,Huang D,Blick T,et al.An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer[J].PLos One,2012,7(1):e29615.
30 Osako Y,Seki N,Kita Y,et al.Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma[J].Int J Oncol,2016,49(6):2255-2264.
31 Jin D,Tao J,Li D,et al.Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion[J].Oncotarget,2015,6(32):33523-33533.
32 Goto Y,Kojima S,Nishikawa R,et al.The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer[J].Oncotarget,2014,5(17):7748-7759.
33 Kojima S,Enokida H,Yoshino H,et al.The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer[J].J Hum Genet,2014,59(2):78-87.
34 Cheng WY,Kandel JJ,Yamashiro DJ,et al.A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma[J].PLoS One,2012;7(4):e34705.
35 Bao YX,Cao Q,Yang Y,et al.Expression and prognostic significance of golgiglycoprotein73(GP73)with epithelial-mesenchymal transition(EMT)related molecules in hepatocellular carcinoma(HCC)[J].Diagn Pathol,2013,8(1):197.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	孟海,杜观祥,朱利玲,汤琪云. WEE1在胃癌组织中的表达及对患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 239-243.
[4]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[5]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[6]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[7]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[8]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[9]	徐晖, 李希, 周春水. 应用以人转录组为靶点的shRNA文库筛选肺癌肿瘤相关抑制基因[J]. 实用肿瘤学杂志, 2019, 33(2): 97-102.
[10]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[11]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[12]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[13]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[14]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[15]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.